Justyna Całka
Justyna Całka has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anita ZięBa
1st Military Clinical Hospital with Outpatient Clinic, SPZOZ, Lublin, Poland
10 shared publications - Dominika Zdobylak
4th Military Clinical Hospital with Outpatient Clinic, SPZOZ, Wrocław, Poland
10 shared publications - Kamil Harenza
Mikołaj Pirogow Provincial Specialist Hospital, Łódź, Poland
10 shared publications - Karolina Ollik
10th Military Clinical Hospital with Outpatient Clinic, SPZOZ, Bydgoszcz, Poland
10 shared publications - Katarzyna Ścibisz
1st Military Clinical Hospital with Outpatient Clinic, SPZOZ, Lublin, Poland
10 shared publications - Mateusz Taranowicz
118th Military Hospital with Outpatient Clinic, SPZOZ, Ełk, Poland
10 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
GLP-1 RECEPTOR AGONISTS IN AESTHETIC MEDICINE: THERAPEUTIC BREAKTHROUGH OR CATALYST FOR UNREALISTIC BODY IDEALS?
GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, have transformed obesity and type 2 diabetes mellitus management through robust weight loss and metabolic benefits. GLP-1 RAs produce substantial weight loss through appetite suppression, delayed gastric emptying, and metabolic modulation. As these agents increasingly enter aesthetic medicine ecosystems - where weight management, body contouring, and skin health intersect with patient expectations about appearance - clinicians face dual questions: Do GLP-1 RAs represent a therapeutic breakthrough for patients seeking aesthetic improvements, or do they risk catalyzing unrealistic body ideals and exacerbating societal pressures around weight and appearance? This review synthesizes mechanistic, clinical, psychosocial, ethical, and regulatory dimensions of GLP-1 RA use in aesthetic contexts, drawing on a broad corpus of literature including recent reviews and primary studies, as well as the provided candidate references and additional sources. We examine (1) pharmacology and clinical efficacy for weight reduction and body composition, (2) esthetic implications of rapid weight loss, including facial volume changes and skin effects, (3) ethical and societal considerations surrounding body ideals, (4) risk–benefit and safety concerns in cosmetic and non-diabetic populations, (5) integration with other aesthetic modalities and multidisciplinary care, and (6) practical guidance for clinicians operating Ozempicin-like aesthetic clinics. We conclude with a framework for responsible, patient-centered deployment of GLP-1–based therapies within aesthetic medicine, emphasizing informed consent, psychosocial screening, realistic expectation management, and equitable access.
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessGLP-1 RECEPTOR AGONISTS IN AESTHETIC MEDICINE: THERAPEUTIC BREAKTHROUGH OR CATALYST FOR UNREALISTIC BODY IDEALS?
GLP-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, have transformed obesity and type 2 diabetes mellitus management through robust weight loss and metabolic benefits. GLP-1 RAs produce substantial weight loss through appetite suppression, delayed gastric emptying, and metabolic modulation. As these agents increasingly enter aesthetic medicine ecosystems - where weight management, body contouring, and skin health intersect with patient expectations about appearance - clinicians face dual questions: Do GLP-1 RAs represent a therapeutic breakthrough for patients seeking aesthetic improvements, or do they risk catalyzing unrealistic body ideals and exacerbating societal pressures around weight and appearance? This review synthesizes mechanistic, clinical, psychosocial, ethical, and regulatory dimensions of GLP-1 RA use in aesthetic contexts, drawing on a broad corpus of literature including recent reviews and primary studies, as well as the provided candidate references and additional sources. We examine (1) pharmacology and clinical efficacy for weight reduction and body composition, (2) esthetic implications of rapid weight loss, including facial volume changes and skin effects, (3) ethical and societal considerations surrounding body ideals, (4) risk–benefit and safety concerns in cosmetic and non-diabetic populations, (5) integration with other aesthetic modalities and multidisciplinary care, and (6) practical guidance for clinicians operating Ozempicin-like aesthetic clinics. We conclude with a framework for responsible, patient-centered deployment of GLP-1–based therapies within aesthetic medicine, emphasizing informed consent, psychosocial screening, realistic expectation management, and equitable access.
- Open Access
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
TEDUGLUTIDE - A GLP-2 ANALOG IN THE TREATMENT OF SHORT BOWEL SYNDROME: A LITERATURE REVIEW
Short bowel syndrome–associated intestinal failure (SBS-IF) is a rare but severe clinical condition characterized by insufficient intestinal absorptive capacity and frequent dependence on long-term parenteral support. Prolonged reliance on parenteral nutrition is associated with substantial morbidity, underscoring the need for targeted therapeutic strategies that enhance intestinal adaptation and reduce intravenous support requirements. Advances in the understanding of gut-derived trophic hormones have identified glucagon-like peptide-2 (GLP-2) as a key regulator of intestinal growth and function, leading to the development of GLP-2–based pharmacological therapies. The aim of this narrative literature review is to critically synthesise current evidence regarding the physiological role of GLP-2, the pharmacological properties of teduglutide, and its clinical efficacy and safety in the management of SBS-IF. A comprehensive literature search was conducted using PubMed and Google Scholar, including randomised controlled trials, observational studies, systematic reviews, and meta-analyses relevant to GLP-2 biology and teduglutide therapy. The available evidence demonstrates that teduglutide enhances intestinal absorptive capacity, promotes mucosal adaptation, and enables clinically meaningful and sustained reductions in parenteral support requirements in both adult and paediatric patients. In selected individuals, treatment may facilitate partial or complete achievement of enteral autonomy. However, given its intestinotrophic mechanism of action, appropriate patient selection, structured monitoring, and long-term safety surveillance remain essential. Overall, teduglutide represents a significant advance in the targeted treatment of SBS-associated intestinal failure.
- 30 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (1(49))
Open AccessTEDUGLUTIDE - A GLP-2 ANALOG IN THE TREATMENT OF SHORT BOWEL SYNDROME: A LITERATURE REVIEW
Short bowel syndrome–associated intestinal failure (SBS-IF) is a rare but severe clinical condition characterized by insufficient intestinal absorptive capacity and frequent dependence on long-term parenteral support. Prolonged reliance on parenteral nutrition is associated with substantial morbidity, underscoring the need for targeted therapeutic strategies that enhance intestinal adaptation and reduce intravenous support requirements. Advances in the understanding of gut-derived trophic hormones have identified glucagon-like peptide-2 (GLP-2) as a key regulator of intestinal growth and function, leading to the development of GLP-2–based pharmacological therapies. The aim of this narrative literature review is to critically synthesise current evidence regarding the physiological role of GLP-2, the pharmacological properties of teduglutide, and its clinical efficacy and safety in the management of SBS-IF. A comprehensive literature search was conducted using PubMed and Google Scholar, including randomised controlled trials, observational studies, systematic reviews, and meta-analyses relevant to GLP-2 biology and teduglutide therapy. The available evidence demonstrates that teduglutide enhances intestinal absorptive capacity, promotes mucosal adaptation, and enables clinically meaningful and sustained reductions in parenteral support requirements in both adult and paediatric patients. In selected individuals, treatment may facilitate partial or complete achievement of enteral autonomy. However, given its intestinotrophic mechanism of action, appropriate patient selection, structured monitoring, and long-term safety surveillance remain essential. Overall, teduglutide represents a significant advance in the targeted treatment of SBS-associated intestinal failure.
- Open Access
- 27 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
EFFICACY AND SAFETY OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF TRIGEMINAL NEURALGIA: A SYSTEMATIC REVIEW OF CLINICAL EVIDENCE
Trigeminal neuralgia (TN) is a severe neuropathic pain disorder characterized by recurrent unilateral, electric shock–like facial pain. The firstly chosen treatments are usually pharmacological therapies. Although, the usage of botulinum toxin (BTX) injections are investigated due to its high levels of safety and effectiveness and low rates of side effects at the same time. This systematic review is focused on an analysis of different studies to confirm the advantages of BTX in the case of TN. In this study there were taken into consideration some randomized controlled trials, prospective studies, open-label studies, and case reports. In total 25 studies were analyzed. The research was focused on the reduction of pain intensity, frequency of recurrence, contentment of patients and rate of side effects. The results showed that BTX-A treatment in TN can be an effective and safe option for the patients. The reduction of pain intensity and frequency of attacks was reported. The findings were supported by some placebo controlled groups. In some cases there was even achieved a complete remission of symptoms. The adverse effects were rare and generally mild and transient. The BTX treatment gave promising results but the long term efficiency should be still investigated. There is also a high need to perform some enlarged studies with standardized procedures of BTX injections which would include the placebo control groups. In conclusion the usage of BTX-A in NT treatment appears to be an effective and safe option and a great alternative to traditional pharmacological therapy.
- 27 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessEFFICACY AND SAFETY OF BOTULINUM TOXIN TYPE A IN THE TREATMENT OF TRIGEMINAL NEURALGIA: A SYSTEMATIC REVIEW OF CLINICAL EVIDENCE
Trigeminal neuralgia (TN) is a severe neuropathic pain disorder characterized by recurrent unilateral, electric shock–like facial pain. The firstly chosen treatments are usually pharmacological therapies. Although, the usage of botulinum toxin (BTX) injections are investigated due to its high levels of safety and effectiveness and low rates of side effects at the same time. This systematic review is focused on an analysis of different studies to confirm the advantages of BTX in the case of TN. In this study there were taken into consideration some randomized controlled trials, prospective studies, open-label studies, and case reports. In total 25 studies were analyzed. The research was focused on the reduction of pain intensity, frequency of recurrence, contentment of patients and rate of side effects. The results showed that BTX-A treatment in TN can be an effective and safe option for the patients. The reduction of pain intensity and frequency of attacks was reported. The findings were supported by some placebo controlled groups. In some cases there was even achieved a complete remission of symptoms. The adverse effects were rare and generally mild and transient. The BTX treatment gave promising results but the long term efficiency should be still investigated. There is also a high need to perform some enlarged studies with standardized procedures of BTX injections which would include the placebo control groups. In conclusion the usage of BTX-A in NT treatment appears to be an effective and safe option and a great alternative to traditional pharmacological therapy.
- Open Access
- 26 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
THE ROLE OF MICROBIAL ENGRAFTMENT AND KEYSTONE SPECIES IN THE EFFICACY OF FAECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - A REVIEW OF RECENT STUDIES
Background: Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, are chronic relapsing disorders in which alterations of the gut microbiota contribute to disease pathogenesis. Despite advances in pharmacological therapies, sustained remission remains difficult to achieve in many patients, prompting interest in microbiome-targeted interventions such as faecal microbiota transplantation. Objectives: This study aimed to review evidence published between 2015 and 2025 on the efficacy of faecal microbiota transplantation in inflammatory bowel diseases, with emphasis on donor microbiota engraftment, keystone taxa, the donor effect, and differences between ulcerative colitis and Crohn’s disease. Methods: A narrative–systematic review of clinical, metagenomic, and ecological studies addressing faecal microbiota transplantation in inflammatory bowel diseases was conducted using major biomedical databases. Results: Clinical response following faecal microbiota transplantation was more consistently associated with stable and functional engraftment of donor-derived microbial strains than with restoration of microbial diversity alone. Evidence supporting this association was stronger in ulcerative colitis, whereas data in Crohn’s disease remained limited and largely observational. Variability in outcomes appeared to reflect interactions between donor and recipient microbiota. Conclusions: Faecal microbiota transplantation represents a complex ecological intervention, the efficacy of which depends on engraftment stability, functional reconstruction of the gut microbiome, and recipient-specific ecological context.
- 26 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessTHE ROLE OF MICROBIAL ENGRAFTMENT AND KEYSTONE SPECIES IN THE EFFICACY OF FAECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE - A REVIEW OF RECENT STUDIES
Background: Inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis, are chronic relapsing disorders in which alterations of the gut microbiota contribute to disease pathogenesis. Despite advances in pharmacological therapies, sustained remission remains difficult to achieve in many patients, prompting interest in microbiome-targeted interventions such as faecal microbiota transplantation. Objectives: This study aimed to review evidence published between 2015 and 2025 on the efficacy of faecal microbiota transplantation in inflammatory bowel diseases, with emphasis on donor microbiota engraftment, keystone taxa, the donor effect, and differences between ulcerative colitis and Crohn’s disease. Methods: A narrative–systematic review of clinical, metagenomic, and ecological studies addressing faecal microbiota transplantation in inflammatory bowel diseases was conducted using major biomedical databases. Results: Clinical response following faecal microbiota transplantation was more consistently associated with stable and functional engraftment of donor-derived microbial strains than with restoration of microbial diversity alone. Evidence supporting this association was stronger in ulcerative colitis, whereas data in Crohn’s disease remained limited and largely observational. Variability in outcomes appeared to reflect interactions between donor and recipient microbiota. Conclusions: Faecal microbiota transplantation represents a complex ecological intervention, the efficacy of which depends on engraftment stability, functional reconstruction of the gut microbiome, and recipient-specific ecological context.
- Open Access
- 25 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
THE COMPARISON OF MONOTHERAPIES OF KELOID SCARS BY LASER, SILICONE GEL, 5-FLUOROURACIL AND CRYOTHERAPY TREATMENTS - A LITERATURE REVIEW
Keloid scars are a common problem of abnormal wound healing. There are plenty of treatment options. There is why, in this review 4 of them (laser, silicone gel, 5-fluorouracil and cryotherapy) were examined separately as monotherapies and compared. The aim of the review was to find out whether there could be found an effective monotherapy of keloids and which one of the examined ones could be the most promising one. In the review there were 28 studies analyzed focused on laser, silicone gel, 5-fluorouracil and intralesional cryotherapy as monotherapies of keloids. They included some randomized controlled trials, systematic reviews, observational studies and in vitro investigations. All the literature based on combined therapies was excluded. The effectiveness, safety and rate of recurrence was assessed. All of the therapies showed some improvements in the appearance of scars and the symptoms. However, the quality of evidence was low due to limitations of the studies and lack of long-term outcomes. Intralesional cryotherapy seems to bring the most promising results but equally the highest risk of side effects. The other 3 methods had very similar results. None of the proposed treatments can be defined as an effective monotherapy of keloid scars. There is a high need of conducting more research focused on standardized procedures with big randomized groups of patients and the follow-ups to examine long-term recurrence rate. It could be also suggested that monotherapy may not be the best way of treatment and the further research should be focused on combined therapies.
- 25 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (1(49))
Open AccessTHE COMPARISON OF MONOTHERAPIES OF KELOID SCARS BY LASER, SILICONE GEL, 5-FLUOROURACIL AND CRYOTHERAPY TREATMENTS - A LITERATURE REVIEW
Keloid scars are a common problem of abnormal wound healing. There are plenty of treatment options. There is why, in this review 4 of them (laser, silicone gel, 5-fluorouracil and cryotherapy) were examined separately as monotherapies and compared. The aim of the review was to find out whether there could be found an effective monotherapy of keloids and which one of the examined ones could be the most promising one. In the review there were 28 studies analyzed focused on laser, silicone gel, 5-fluorouracil and intralesional cryotherapy as monotherapies of keloids. They included some randomized controlled trials, systematic reviews, observational studies and in vitro investigations. All the literature based on combined therapies was excluded. The effectiveness, safety and rate of recurrence was assessed. All of the therapies showed some improvements in the appearance of scars and the symptoms. However, the quality of evidence was low due to limitations of the studies and lack of long-term outcomes. Intralesional cryotherapy seems to bring the most promising results but equally the highest risk of side effects. The other 3 methods had very similar results. None of the proposed treatments can be defined as an effective monotherapy of keloid scars. There is a high need of conducting more research focused on standardized procedures with big randomized groups of patients and the follow-ups to examine long-term recurrence rate. It could be also suggested that monotherapy may not be the best way of treatment and the further research should be focused on combined therapies.
- Open Access
- 24 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
TRANSAXILLARY AORTIC VALVE REPLACEMENT AS AN ALTERNATIVE TO CURRENT TREATMENT METHODS
Introduction and aim: The aortic valve consists of three lobes, often presenting as a bilobed congenital heart defect. It is responsible for the outflow of blood from the left ventricle into the aorta by preventing backflow of blood into the heart during left ventricular diastole. The most common health problems associated with the aortic valve include stenosis and regurgitation. In minor defects, regular pharmacological treatment may be sufficient. In larger defects, these are available and necessary for treatment; they often require a mechanical valve. The aim of this paper is to review the availability of transaxillary access for aortic valve replacement as an emergency treatment method and its compatibility with current alternatives. The advantages and disadvantages of this treatment are highlighted. Materials and Methods: This narrative review was based on a structured analysis of published clinical trials, extension studies, and review articles evaluating, clinical efficacy, complications in patients with surgical methods for aortic stenosis defects. Results: A significant number of people with aortic valve disease can be managed with minimally invasive monitoring and do not require radical treatment. However, if the defect is severe, surgical treatment is necessary. Aortic valve replacement is currently treated using three basic methods. The first is a classic sternotomy, which involves opening the chest by splitting the sternum. The second method is percutaneous valve implantation: TAVI. Recently, thanks to the use of modern equipment, minimally invasive surgical techniques have become available, including: partial upper sternotomy, mini-sternotomy, and right anterior mini-thoracotomy. During surgery, two types of valves can be implanted: mechanical or biological. Each is preferred by different groups of patients and carries different consequences. Therefore, when qualifying for the procedure, it is crucial to consider the patient's preferences, as well as a thorough analysis of the clinical situation by a team of experts. Conclusions: The transaxillary approach is a more invasive method than TAVI, but less invasive than the sternotomy approach. This allows for shorter recovery times after the procedure, with more thorough cleaning and valve adjustment than with TAVI. At the same time, this method requires greater operator dexterity, as access is limited compared to traditional incisions, both in terms of space for instruments and visibility.
- 24 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
Open AccessTRANSAXILLARY AORTIC VALVE REPLACEMENT AS AN ALTERNATIVE TO CURRENT TREATMENT METHODS
Introduction and aim: The aortic valve consists of three lobes, often presenting as a bilobed congenital heart defect. It is responsible for the outflow of blood from the left ventricle into the aorta by preventing backflow of blood into the heart during left ventricular diastole. The most common health problems associated with the aortic valve include stenosis and regurgitation. In minor defects, regular pharmacological treatment may be sufficient. In larger defects, these are available and necessary for treatment; they often require a mechanical valve. The aim of this paper is to review the availability of transaxillary access for aortic valve replacement as an emergency treatment method and its compatibility with current alternatives. The advantages and disadvantages of this treatment are highlighted. Materials and Methods: This narrative review was based on a structured analysis of published clinical trials, extension studies, and review articles evaluating, clinical efficacy, complications in patients with surgical methods for aortic stenosis defects. Results: A significant number of people with aortic valve disease can be managed with minimally invasive monitoring and do not require radical treatment. However, if the defect is severe, surgical treatment is necessary. Aortic valve replacement is currently treated using three basic methods. The first is a classic sternotomy, which involves opening the chest by splitting the sternum. The second method is percutaneous valve implantation: TAVI. Recently, thanks to the use of modern equipment, minimally invasive surgical techniques have become available, including: partial upper sternotomy, mini-sternotomy, and right anterior mini-thoracotomy. During surgery, two types of valves can be implanted: mechanical or biological. Each is preferred by different groups of patients and carries different consequences. Therefore, when qualifying for the procedure, it is crucial to consider the patient's preferences, as well as a thorough analysis of the clinical situation by a team of experts. Conclusions: The transaxillary approach is a more invasive method than TAVI, but less invasive than the sternotomy approach. This allows for shorter recovery times after the procedure, with more thorough cleaning and valve adjustment than with TAVI. At the same time, this method requires greater operator dexterity, as access is limited compared to traditional incisions, both in terms of space for instruments and visibility.
- Open Access
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
NEW DISEASE-MODIFYING THERAPIES IN ALZHEIMER’S DISEASE: A CLINICAL REVIEW OF LECANEMAB AND DONANEMAB
It has been widely suggested that monoclonal antibodies targeting amyloid-β represent a potentially disease-modifying therapeutic approach for Alzheimer’s disease (AD), offering an alternative to purely symptomatic treatments. In recent years, considerable research attention has focused on anti-amyloid strategies aimed at modifying the underlying pathophysiology of early symptomatic AD. Among the agents currently under investigation, lecanemab and donanemab have demonstrated consistent amyloid plaque reduction and statistically significant slowing of cognitive and functional decline in patients with mild cognitive impairment or mild dementia due to AD. The present review aims to critically evaluate evidence from pivotal clinical trials of both therapies, with particular emphasis on efficacy outcomes, safety profiles, pharmacological characteristics, and regulatory approval status. Special attention is given to treatment-related risks, including amyloid-related imaging abnormalities (ARIA), as well as factors influencing patient eligibility, treatment initiation, and monitoring strategies in clinical practice. Taken together, the available evidence suggests that amyloid-targeting monoclonal antibodies may provide a modest yet clinically meaningful benefit in carefully selected patients, while simultaneously highlighting ongoing challenges related to safety, implementation, and long-term therapeutic effectiveness.
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
Open AccessNEW DISEASE-MODIFYING THERAPIES IN ALZHEIMER’S DISEASE: A CLINICAL REVIEW OF LECANEMAB AND DONANEMAB
It has been widely suggested that monoclonal antibodies targeting amyloid-β represent a potentially disease-modifying therapeutic approach for Alzheimer’s disease (AD), offering an alternative to purely symptomatic treatments. In recent years, considerable research attention has focused on anti-amyloid strategies aimed at modifying the underlying pathophysiology of early symptomatic AD. Among the agents currently under investigation, lecanemab and donanemab have demonstrated consistent amyloid plaque reduction and statistically significant slowing of cognitive and functional decline in patients with mild cognitive impairment or mild dementia due to AD. The present review aims to critically evaluate evidence from pivotal clinical trials of both therapies, with particular emphasis on efficacy outcomes, safety profiles, pharmacological characteristics, and regulatory approval status. Special attention is given to treatment-related risks, including amyloid-related imaging abnormalities (ARIA), as well as factors influencing patient eligibility, treatment initiation, and monitoring strategies in clinical practice. Taken together, the available evidence suggests that amyloid-targeting monoclonal antibodies may provide a modest yet clinically meaningful benefit in carefully selected patients, while simultaneously highlighting ongoing challenges related to safety, implementation, and long-term therapeutic effectiveness.
- Open Access
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
THE IMPACT OF ANTIBIOTIC THERAPY ON THE EFFECTIVENESS OF IMMUNOTHERAPY: A REVIEW OF CURRENT EVIDENCE
Background: Immune checkpoint inhibitors have transformed cancer treatment, yet only a subset of patients achieve durable clinical benefit. Increasing evidence indicates that the intestinal microbiota plays a key role in regulating antitumor immune responses. Antibiotic therapy, by disrupting microbial homeostasis, may negatively influence the effectiveness of immunotherapy. Objectives: This narrative review aims to synthesize current preclinical and clinical evidence regarding the impact of antibiotic exposure on the efficacy of immune checkpoint inhibitor therapy, with particular attention to timing of exposure, tumor type, and underlying biological mechanisms. Methods: A focused literature search was conducted using major biomedical databases to identify relevant preclinical studies, retrospective and prospective clinical cohorts, and systematic reviews examining the relationship between antibiotic use and immunotherapy outcomes. Due to heterogeneity in study design and exposure definitions, findings were analyzed narratively. Results: Across multiple tumor types, antibiotic exposure was consistently associated with inferior clinical outcomes, including reduced progression-free survival, overall survival, and treatment response. The negative association was most pronounced when antibiotics were administered shortly before initiation of immunotherapy. Meta-analyses confirmed the robustness of this signal despite substantial heterogeneity and methodological limitations. Emerging translational and early interventional studies suggest that modulation of the gut microbiome may partially restore immunotherapy responsiveness. Conclusions: Current evidence supports a clinically relevant association between antibiotic exposure and reduced immunotherapy efficacy. While causality cannot be definitively established, these findings highlight the importance of judicious antibiotic use in patients receiving immunotherapy and underscore the need for prospective, microbiome-integrated studies to guide future clinical practice.
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
Open AccessTHE IMPACT OF ANTIBIOTIC THERAPY ON THE EFFECTIVENESS OF IMMUNOTHERAPY: A REVIEW OF CURRENT EVIDENCE
Background: Immune checkpoint inhibitors have transformed cancer treatment, yet only a subset of patients achieve durable clinical benefit. Increasing evidence indicates that the intestinal microbiota plays a key role in regulating antitumor immune responses. Antibiotic therapy, by disrupting microbial homeostasis, may negatively influence the effectiveness of immunotherapy. Objectives: This narrative review aims to synthesize current preclinical and clinical evidence regarding the impact of antibiotic exposure on the efficacy of immune checkpoint inhibitor therapy, with particular attention to timing of exposure, tumor type, and underlying biological mechanisms. Methods: A focused literature search was conducted using major biomedical databases to identify relevant preclinical studies, retrospective and prospective clinical cohorts, and systematic reviews examining the relationship between antibiotic use and immunotherapy outcomes. Due to heterogeneity in study design and exposure definitions, findings were analyzed narratively. Results: Across multiple tumor types, antibiotic exposure was consistently associated with inferior clinical outcomes, including reduced progression-free survival, overall survival, and treatment response. The negative association was most pronounced when antibiotics were administered shortly before initiation of immunotherapy. Meta-analyses confirmed the robustness of this signal despite substantial heterogeneity and methodological limitations. Emerging translational and early interventional studies suggest that modulation of the gut microbiome may partially restore immunotherapy responsiveness. Conclusions: Current evidence supports a clinically relevant association between antibiotic exposure and reduced immunotherapy efficacy. While causality cannot be definitively established, these findings highlight the importance of judicious antibiotic use in patients receiving immunotherapy and underscore the need for prospective, microbiome-integrated studies to guide future clinical practice.
- Open Access
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
THERAPEUTIC OPTIONS IN ENDOMETRIOSIS: A COMPARATIVE LITERATURE REVIEW OF INTRAUTERINE DEVICE THERAPY, SURGICAL TREATMENT, RELUGOLIX COMBINATION THERAPY, AND DIENOGEST
Endometriosis is a chronic, estrogen-dependent disease affecting women of reproductive age, associated with chronic pelvic pain, impaired fertility, and significant impairment of quality of life. The heterogeneous clinical presentation, variable disease severity, and high recurrence rates make therapeutic decision-making particularly challenging. This review summarizes and critically compares current evidence regarding four commonly used treatment modalities: the levonorgestrel-releasing intrauterine system (LNG-IUS), relugolix combination therapy, surgical intervention, and dienogest. The analysis focuses on their effectiveness in symptom reduction, safety profile, and suitability for long-term management. A review of randomized controlled trials and meta-analyses demonstrates that all reviewed modalities provide meaningful pain relief, though clinical applicability differs substantially. Surgical treatment, particularly laparoscopic excision, offers rapid symptom improvement, especially in deep infiltrating endometriosis, but is limited by invasiveness and recurrence risk. Dienogest and levonorgestrel-releasing intrauterine system represent minimally invasive hormonal options with sustained analgesic efficacy and favorable safety profiles, making them valuable for long-term disease control and postoperative maintenance. Relugolix combination therapy has emerged as a potent oral treatment for severe symptoms with acceptable long-term safety when combined with add-back therapy, although cost and monitoring requirements may limit its use. No single therapeutic approach can be universally recommended for all patients. Optimal management requires an individualized strategy that balances efficacy, safety, and long-term tolerability. Minimally invasive hormonal therapies offer the most favorable balance for long-term management, while surgery and relugolix therapy remain essential options for selected or refractory cases.
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
Open AccessTHERAPEUTIC OPTIONS IN ENDOMETRIOSIS: A COMPARATIVE LITERATURE REVIEW OF INTRAUTERINE DEVICE THERAPY, SURGICAL TREATMENT, RELUGOLIX COMBINATION THERAPY, AND DIENOGEST
Endometriosis is a chronic, estrogen-dependent disease affecting women of reproductive age, associated with chronic pelvic pain, impaired fertility, and significant impairment of quality of life. The heterogeneous clinical presentation, variable disease severity, and high recurrence rates make therapeutic decision-making particularly challenging. This review summarizes and critically compares current evidence regarding four commonly used treatment modalities: the levonorgestrel-releasing intrauterine system (LNG-IUS), relugolix combination therapy, surgical intervention, and dienogest. The analysis focuses on their effectiveness in symptom reduction, safety profile, and suitability for long-term management. A review of randomized controlled trials and meta-analyses demonstrates that all reviewed modalities provide meaningful pain relief, though clinical applicability differs substantially. Surgical treatment, particularly laparoscopic excision, offers rapid symptom improvement, especially in deep infiltrating endometriosis, but is limited by invasiveness and recurrence risk. Dienogest and levonorgestrel-releasing intrauterine system represent minimally invasive hormonal options with sustained analgesic efficacy and favorable safety profiles, making them valuable for long-term disease control and postoperative maintenance. Relugolix combination therapy has emerged as a potent oral treatment for severe symptoms with acceptable long-term safety when combined with add-back therapy, although cost and monitoring requirements may limit its use. No single therapeutic approach can be universally recommended for all patients. Optimal management requires an individualized strategy that balances efficacy, safety, and long-term tolerability. Minimally invasive hormonal therapies offer the most favorable balance for long-term management, while surgery and relugolix therapy remain essential options for selected or refractory cases.
- Open Access
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
ACROMEGALY: CURRENT MANAGEMENT AND THE EMERGING ROLE OF ORAL PALTUSOTINE
Introduction and aim: Acromegaly is a chronic endocrine disorder caused by sustained excess secretion of growth hormone and insulin-like growth factor I, leading to significant morbidity and increased mortality if inadequately treated. Transsphenoidal surgery remains the primary therapeutic approach; however, a substantial proportion of patients fail to achieve durable biochemical remission and require long-term medical therapy. Injectable somatostatin receptor ligands are effective but are associated with treatment burden, variable biochemical responses, and impaired quality of life. The aim of this review was to summarize current management strategies for acromegaly and to evaluate the emerging role of paltusotine, a novel orally administered somatostatin receptor agonist. Materials and Methods: This narrative review was based on a structured analysis of published clinical trials, extension studies, and review articles evaluating the pharmacological properties, clinical efficacy, and safety of paltusotine in patients with acromegaly. Results: Available evidence indicates that paltusotine provides effective suppression of growth hormone secretion and reduction of insulin-like growth factor I levels with once-daily oral administration. Clinical studies demonstrate maintenance of biochemical control in patients previously treated with injectable therapies, as well as efficacy in selected untreated individuals. Paltusotine was generally well tolerated, with predominantly mild gastrointestinal adverse events and elimination of injection-related complications. Conclusions: Paltusotine represents a promising oral alternative to injectable somatostatin receptor ligands, with the potential to reduce treatment burden, improve adherence, and maintain biochemical control. Further long-term and real-world studies are needed to fully define its role in routine clinical practice.
- 2 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (1(49))
Open AccessACROMEGALY: CURRENT MANAGEMENT AND THE EMERGING ROLE OF ORAL PALTUSOTINE
Introduction and aim: Acromegaly is a chronic endocrine disorder caused by sustained excess secretion of growth hormone and insulin-like growth factor I, leading to significant morbidity and increased mortality if inadequately treated. Transsphenoidal surgery remains the primary therapeutic approach; however, a substantial proportion of patients fail to achieve durable biochemical remission and require long-term medical therapy. Injectable somatostatin receptor ligands are effective but are associated with treatment burden, variable biochemical responses, and impaired quality of life. The aim of this review was to summarize current management strategies for acromegaly and to evaluate the emerging role of paltusotine, a novel orally administered somatostatin receptor agonist. Materials and Methods: This narrative review was based on a structured analysis of published clinical trials, extension studies, and review articles evaluating the pharmacological properties, clinical efficacy, and safety of paltusotine in patients with acromegaly. Results: Available evidence indicates that paltusotine provides effective suppression of growth hormone secretion and reduction of insulin-like growth factor I levels with once-daily oral administration. Clinical studies demonstrate maintenance of biochemical control in patients previously treated with injectable therapies, as well as efficacy in selected untreated individuals. Paltusotine was generally well tolerated, with predominantly mild gastrointestinal adverse events and elimination of injection-related complications. Conclusions: Paltusotine represents a promising oral alternative to injectable somatostatin receptor ligands, with the potential to reduce treatment burden, improve adherence, and maintain biochemical control. Further long-term and real-world studies are needed to fully define its role in routine clinical practice.